National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (NCIPC/CDC) at http://www.cdc.gov/ncipc/

Centers for Disease Control and Prevention (CDC) at http://www.cdc.gov/

National Center for Injury Prevention and Control (NCIPC/CDC) at http://www.cdc.gov/ncipc/

If you do not have access to the Internet, or if you have difficulty accessing the forms online, you may contact the CDC Procurement and Grants Office Technical Information Management Section (PGOTIMS) staff. For this, or further assistance, contact PGO TIMS: Telephone (770) 488-2700, Email: PGOTIM@cdc.gov.

This FOA must be read in conjunction with the application package instructions included with this announcement on Grants.gov/Apply for Grants (hereafter referred to as, Grants.gov/Apply.)

A registration process is necessary before submission, and applicants are highly encouraged to start the process at least four weeks prior to the grant submission date. See Section IV.

The application must be successfully received by Grants.gov no later than 5:00 p.m. Eastern Standard Time on the application submission receipt date (see "Key Dates" below.)

Release/Posted Date: October 10. 2007

Letter of Intent Receipt Date: January 19, 2007

Application Submission Receipt Date: February 20, 2007

Peer Review Date: May 2007

Council Review Date: June 2007

Earliest Anticipated Start Date: September 15, 2007

Additional Information to Be Available Date: November 1, 2006

Technical assistance will be available for potential applicants on one conference call. The call for eligible applicants will be held on November 1, 2006, at 1:00 p.m. (Eastern Time). The conference call can be accessed by calling 1-800-369-1121 and using access code LPATTERSON. At the time of the call, if you have problems accessing the conference call, please call 1-800-857-8777 for assistance.

Expiration Date: February 21, 2007

Executive Order 12372 does not apply to this program.

Part I Overview Information

Part II Full Text of Announcement

Section I. Funding Opportunity Description
   1. Research Objectives

Section II. Award Information
   1. Mechanism(s) of Support
   2. Funds Available

Section III. Eligibility Information
   1. Eligible Applicants
       A. Eligible Institutions
       B. Eligible Individuals
   2. Cost Sharing or Matching
   3. Other - Special Eligibility Criteria

Section IV. Application and Submission Information
   1. Request Application Information
   2. Content and Form of Application Submission
   3. Submission Dates and Times
       A. Receipt and Review and Anticipated Start Dates
           1. Letter of Intent
       B. Submitting an Application to CDC
       C. Application Processing
   4. Intergovernmental Review
   5. Funding Restrictions
   6. Other Submission Requirements

Section V. Application Review Information
   1. Criteria
   2. Review and Selection Process
       A. Additional Review Criteria
       B. Additional Review Considerations
       C. Sharing Research Data
       D. Sharing Research Resources
   3. Anticipated Announcement and Award Dates

Section VI. Award Administration Information
   1. Award Notices
   2. Administrative and National Policy Requirements
       A. Cooperative Agreement
           1. Recipient Rights and Responsibilities
           2. CDC Responsibilities
           3. Collaborative Responsibilities
  3. Reporting

Section VII. Agency Contact(s)
   1. Scientific/Research Contact(s)
   2. Peer Review Contact(s)
   3. Financial/ Grants Management Contact(s)
   4. General Questions Contact(s)

Section VIII. Other Information - Required Federal Citations

1. Research Objectives

The overall goal of this FOA is to fund rigorous trials of interventions for the primary prevention of physical intimate partner violence (IPV). Specifically, the FOA seeks to fund interventions that address either family factors or dyadic factors. Primary prevention strategies for IPV have focused almost exclusively on school-based individual-level interventions aimed at changing adolescents’ knowledge, attitudes, and behaviors (Avery-Leaf and Cascardi, 2002; Hickman, Jaycox, & Aronoff, 2004; Whitaker, Morrison, Lindquist, et al., 2006). A number of studies, however, document the importance of factors beyond the individual level that are promising but untested venues for the primary prevention of IPV. As described below, it has become clear that, in many cases, interpersonal behavior patterns learned in the family environment, particularly around aggression and communication, are predictive of later functioning in intimate relationships including the perpetration of IPV. Two ways to disrupt those processes and prevent IPV are by focusing on the family environment or by focusing on the dyadic environment. The background for each of these areas is described as follows.

Family processes: Family processes play a formative role in the development of behavior in intimate relationships. Recent data suggest that family processes are important in understanding the development of violent behavior within an intimate relationship and that parental factors may be useful in preventing IPV. For example, Capaldi and Clark (1998) found that parental dyadic aggression and unskilled parenting (i.e., low parental monitoring, use of harsh discipline) when boys were in elementary school predicted aggression toward a partner approximately eight years later. Other studies have found that parent-child communication patterns predict partner violence up to ten years later (Andrews et al, 2000; Ehrensaft et al., 2003; Lavoi et al., 2002; Linder and Collins, 2005), and that early problem behaviors – a variable that is related to and can be affected by parenting practices – predicts later perpetration of intimate partner violence (Capaldi & Clark, 1998; Ehrensaft et al., 2003; Magdol, Moffitt, Caspi, Newman, Fagan, Silva, 1997; Magdol, Moffitt, Caspi, & Silva 1998). Thus, family processes appear to be important in the development of IPV. This suggests that family-based interventions that target parents and their children, and that are aimed at changing parenting practices and communication strategies could be used to prevent partner violence.

Dyadic processes: Dyadic processes refer to dynamics between partners in a relationship, such as patterns of communication and conflict, and relationship history and behavior. A series of research findings indicate the importance of dyadic processes in both the etiology and prevention of IPV. For example, studies have shown that:

• Violent episodes between partners usually begin with relationship conflict (Cascardi and Vivian, 1995)

• Violent couples have different interaction patterns than non-violent couples (Burman, John, & Margolin, 1992)

• Individuals with antisocial tendencies tend to partner together (Kim & Capaldi, 2004; Moffitt, Caspi, Rutter, & Silva, 2001)

• IPV often involves both partners as perpetrators and victims (Brush, 1990; Caetano, Ramisetty-Mikler, Field, 2005; Gray & Foshee, 1997; Stith et al., 2004; Straus & Gelles, 1995)

• Perpetration of IPV is inconsistent across relationships (Whitaker, Le, & Niolon, 2006)

• Interpersonal processes learned in childhood and adolescence through interactions with parents reveal themselves in later intimate relationship functioning, including partner violence (Andrews et al, 2000; Linder and Collins, 2005).

Thus, there is strong evidence that interpersonal processes within relationships relate to IPV. Dyadic strategies that engage both members of a couple have shown promise in reducing partner violence (Stith, Rosen, McCollum, & Thomsen, 2004; Whitaker, Baker, & Arias, 2006), even when the focus of the intervention is on substance use rather than violence (O’Farrell, Fals-Stewart, Murphy, Stephan, & Murphy, 2004). Thus, dyadic interventions that promote skill-based changes in relationship behavior hold promise for the primary prevention of intimate partner violence, especially because such efforts can be built on the strong existing science of couples-counseling and relationship functioning.

The growing evidence regarding the importance of family and dyadic factors in the perpetration of IPV suggests that each may be a useful venue for primary prevention of IPV. The goal of this FOA is to develop, implement, and rigorously test the impact of either a family-based prevention strategy or a dyad-based prevention strategy on the outcome of physical IPV perpetration and the mediators identified by the intervention strategy with populations that are at risk for IPV. This FOA is intended to fund projects focusing on primary prevention of physical IPV. Primary prevention is defined as preventing a behavior or condition before it occurs. Accordingly, interventions to be funded by this FOA must be targeted at populations at risk for perpetrating physical IPV (i.e., selected populations who have at least one identified risk factor), but not at populations who have already engaged in physical IPV (e.g., participants in batterer prevention programs; partners of women in domestic violence shelters; couples who are engaged in regular, ongoing IPV where the goal of the intervention is to reduce that IPV).

Applications are expected to adhere to high standards of scientific rigor and should include the following elements:

• Theoretical and empirical justification for the proposed intervention for preventing intimate partner violence perpetration;

• Justification for the targeted population, including how the population meets criteria as appropriate for primary prevention; that is, the population is at risk for IPV, but has not already engaged in physical IPV. Note that family-based interventions should focus on preventing IPV behavior of the children/adolescents in the study, and selection of families should be justified based on risk factors (e.g., families whose parents display poor parenting practices, families in which the parents have a history of violence, children with conduct problems);

• Applicants who propose family-based strategies should consider age at enrollment to ensure that participants are of sufficient age at the end of the assessment period to document IPV;

• Methodologically rigorous evaluation designs, namely experimental designs, or strong quasi-experimental designs in which families are matched appropriately on relevant characteristics;

• Appropriate measurement time points that include baseline or pre-intervention assessments, post-intervention measurement, and at least two follow-up data collection points that are sufficient to demonstrate a reliable preventive effect;

• Measures should be reliable, valid, appropriate for the targeted population, and conceptually aligned with the proposed outcomes and mediators. A valid and reliable measure of intimate partner violence perpetration should be selected as an outcome; short-term mediators or proxy measures for outcomes should be described (e.g., conflict and communication for dyadic based strategies; parent-child communication, parent child relationship factors for family-based strategies);

• Data collected from multiple sources to maximize the validity and reliability of the measures. For example, measures of dyadic processes or parent-child processes would ideally be collected from both parties. Observational measures are desirable wherever possible;

• Plans to assess and track fidelity of intervention exposure;

• Data analysis plans should be appropriate to the intervention, research design and hypotheses, measures, and project period. Specifically, analytic plans should consider the unit of assignment of the research design (e.g., should take into account any clustering of data) and multiple sources of data where available (e.g., appropriate plans for analyzing dyadic data should be included);

• An appropriate power analysis that demonstrates a sufficient sample size to detect a primary prevention effect on the main study outcome of IPV within the project period;

• Applicants who propose dyadic strategies must describe steps that will be taken to ensure that only appropriate dyads will be enrolled in the dyadic intervention. For instance, dyadic strategies to prevent partner violence would not be appropriate when there is a high degree of control exerted by one partner over the other, high levels of fear from one partner to the other. Relevant discussion on this topic is provided by O’Leary (2002), Bograd and Mederos (1999), and Stith, Rosen, & McCollum (2002).

The HHS/CDC U49 is a cooperative agreement assistance instrument. Under the Cooperative Agreement assistance instrument, the Recipient Organization retains the primary responsibility and dominant role for planning, directing, and executing the proposed project, and with HHS/CDC staff is substantially involved as a partner with the Recipient Organization, as described in Section VI.2.A., "Cooperative Agreement".

The participating Centers, Institutes, and Offices (CIO)(s) (NCIPC) intends to commit approximately $800,000 (to include direct and indirect costs) in FY2007 to fund two applications. The average award amount will be $400,000 for the first 12-month period, including direct and indirect costs. An applicant may request a project period of up to five years, and may request up to $400,000 for the first 12-month budget period, including direct and indirect costs. The approximate total project period funded amount is $2 million per project. The anticipated start date for new awards is September, 2007.

All estimated funding amounts are subject to availability of funds.

If an applicant requests a funding amount greater than the ceiling of the award range, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirements.

Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the CIO (s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.

Facilities and Administrative (F&A) costs requested by consortium participants are not included in the direct cost limitation. See NOT-OD-05-004.  

You may submit an application if your organization has any of the following characteristics:

Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Additionally,

If your application is incomplete or non-responsive to the special requirements listed in this section, it will not be entered into the review process.

Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, or loan.

To download a SF424 (R&R) Application Package and SF424 (R&R) Application Instructions for completing the SF424 (R&R) forms for this FOA, link to http://www.grants.gov/Apply/  and follow the directions provided on that Web site.

A one-time registration is required for institutions/organizations at the following:

Note: CDC strongly encourages all applicants (both Organizations and Project Directors/Principal Investigators [PD/PI]) to also register in Electronic Research Administration (eRA Commons) as soon as possible (see below). Although an eRA Commons account is not mandatory at this time, future FOAs may require your participation in eRA Commons to complete an electronic application submission through Grants.gov. Important information on registration can be obtained at the following:

PD/PIs should work with their institutions/organizations to make sure they are registered in the eRA Commons.

Applicant institutions/organizations should complete the following actions as soon as possible:

1) Organizational/Institutional Registration in Grants.gov Get Registered

2) Organizational/Institutional Registration in the eRA Commons

3) Project Director/Principal Investigator (PD/PI) Registration in the eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.

Note that if a PD/PI is also an HHS peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only. These are different than any DUNS number and CCR registration used by an applicant organization. Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Government.

Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered in both Grants.gov and the eRA Commons. The HHS/CDC strongly encourages applicants to use the Grants.gov electronic applications process and have organizations and PD/PIs complete all necessary registrations.

If you do not have access to the Internet, or if you have difficulty accessing the forms online, you may contact the CDC Procurement and Grants Office Technical Information Management Section (PGOTIMS) staff. For this, or further assistance, contact PGO TIMS: Telephone (770) 488-2700, Email: PGOTIM@cdc.gov.

Prepare all applications using the SF424 (R&R) application forms and in accordance with the SF424 (R&R) Application Guide (MS Word or PDF).

The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to HHS/CDC.

The SF424 (R&R) application is comprised of data arranged in separate components. Some components are required, others are optional. The forms package associated with this FOA in Grants.gov/APPLY will include all applicable components, mandatory and optional. A completed application in response to this FOA will include the following components:

SF424 (R&R) (Cover component)
Research & Related Project/Performance Site Locations
Research & Related Other Project Information
Research & Related Senior/Key Person
Research & Related Budget
PHS398 Cover Page Supplement
PHS398 Research Plan
PHS398 Checklist

Note: While both budget components are included in the SF424 (R&R) forms package, the CDC U49 (activity code) uses ONLY the detailed Research & Related Budget. (Do not use the PHS 398 Modular Budget.)

See Section IV.3.A for details

Earliest Anticipated Start Date: September 15, 2007

Prospective applicants are asked to submit a letter of intent that includes the following information:

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows CDC Program staff to estimate the potential review workload and plan the review.

The letter of intent is to be sent by the date listed in Section IV.3.A

The letter of intent should be sent by mail, fax or email to:

NCIPC Extramural Resources Team

CDC, National Center for Injury Prevention and Control

Address for Express Mail or Delivery Service:

2945 Flowers Rd. S.

Yale Building, Room 2054

Atlanta, GA 30341

Address for U.S. Postal Service Mail:

4770 Buford Hwy. NE, Mailstop K-62

Atlanta, GA 30341

Telephone: (770) 488-4037
FAX: (770) 488-1662
Email: CIPERT@cdc.gov

If the instructions in this announcement differ in any way from the SF424 R&R instructions, follow the instructions in this announcement.

To submit an application in response to this FOA, applicants should access this FOA via http://www.grants.gov/Apply  and follow steps 1-4. If submittal of the application is done electronically through Grants.gov http://www.grants.gov , the application will be electronically time/date stamped by Grants.gov. Applicants will receive an e-mail notice of receipt from Grants.gov when HHS/CDC receives the application.

All requested information must be received in the HHS/CDC Procurement and Grants Office by 5:00 p.m. Eastern Standard Time on the deadline date. If an applicant submits materials by the United States Postal Service or commercial delivery service, you must ensure that the carrier will be able to guarantee delivery by the closing date and time. If HHS/CDC receives your submission after closing because of : (1) carrier error, when the carrier accepted the package with a guarantee for delivery by the closing date and time, or (2) significant weather delays or natural disasters, you have the opportunity to submit documentation of the carrier’s guarantee. If the documentation verifies a carrier problem, HHS/CDC will consider the submission as having been received by the deadline.

This announcement is the definitive guide on Letter Of Intent (LOI) and application content, submission address, and deadline. It supersedes information provided in the application instructions. If your application does not meet the deadline described in Section IV.3.A, it will not be eligible for review, and HHS/CDC will discard it. You will receive notification that you did not meet the submission requirements.

If submitting a paper application, it must be prepared using the 424 R&R instructions for preparing a research grant application. Submit a signed, typewritten original of the application and all appendices, including the checklist, and three signed photocopy(s) to the following address:

Technical Information Management Section – RFA-CDC-CE07-002

CDC, Procurements and Grants Office

U.S. Department of Health and Human Services

2920 Brandywine Road

Atlanta, GA 30341

Phone: 770-488-2700

Note that HHS/CDC will currently not be using the eRA Commons system for processing of electronic applications unless otherwise stated in the FOA. HHS/CDC encourages all applicants to get registered in eRA Commons to be able to review summary statements and review scores which can be found in eRA Commons.

Upon receipt, applications will be evaluated for completeness and responsiveness by NCIPC and HHS/CDC Procurement and Grants Office (PGO). HHS/CDC will not review incomplete or non-responsive applications.

There will be an acknowledgement of receipt of applications from Grants.gov.

Executive Order 12372 does not apply to this program.

All HHS/CDC awards are subject to the terms and conditions, cost principles, and other considerations described in the HHS/PHS Grants Policy Statement.

Awardees, upon acceptance of Notice of Award (NoA), must agree to the "Cooperative Agreement Terms and Conditions of Award" in Section VI. "Award Administration Information."

If you are requesting indirect costs in your budget, you must include a copy of your indirect cost rate agreement. If your indirect cost rate is a provisional rate, the agreement should be less than 12 months of age. If submitting electronically, use a PDF version of the agreement, attach it in Grants.gov under "Other Attachments", and title it appropriately.

Applicants’ research plan(s) should address activities they will conduct over the entire project period.

While each section of the Research Plan component needs to be uploaded separately as a PDF attachment, applicants are encouraged to construct the Research Plan component as a single document, separating sections into distinct PDF attachments just before uploading the files. This approach will enable applicants to better monitor formatting requirements such as page limits. All attachments must be provided to HHS/CDC in PDF format, filenames must be included with no spaces or special characters, and a .pdf extension must be used. Do not include any information in a header or footer of the attachments. A header will be system-generated that references the PD/PI. Page numbers for the footer will be system-generated in the complete application, with all pages sequentially numbered; therefore, do not number the pages of your attachments.  Your research plan must not exceed 25 pages. If your research plan exceeds the page limitation, your application may be considered unresponsive and ineligible for review.

The following materials may be included in the Appendix:

Up to five publications, manuscripts (accepted for publication), abstracts, patents, or other printed materials directly relevant to the proposed project. Do not include manuscripts submitted for publication. Applicants should refer to instruction guides and specific Funding Opportunity Announcements (FOAs) to determine the appropriate limit on the number of publications that may be submitted for a particular program. Note that not all grant activity codes allow the inclusion of publications.

Do not use the Appendix to circumvent the page limitations of the Research Plan component. An application that does not observe the relevant policies and procedures may not be considered in the review process. Applicants are reminded to review specific FOAs for any additional program-specific guidance on Appendix material and other application requirements.

Only the review criteria described below will be considered in the review process.

The goals of HHS/CDC-supported research are to advance the understanding of health promotion and the prevention of disease, injury, and disability, and enhance preparedness. In the written comments, evaluate the application to judge the likelihood the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed by the reviewers and considered in assigning the overall score, weighting them as appropriate for each application.

For dyadic interventions, there must be sufficient discussion of conditions under which dyads would be excluded. Dyadic approaches for the prevention of IPV are not appropriate under all circumstances. Several peer-reviewed papers have provided guidance on when dyadic strategies may and may not be appropriate (e.g., Bograd and Mederos, 1999; O’Leary, 2001; Stith, Rosen, & McCollum, 2002).

Innovation: Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?

Investigators: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)? Does the PI have documented prior experience in conducting research that has focused on the chosen priority area (i.e., either family-based interventions to prevent problem behaviors, or dyadic interventions to change relationship processes/outcomes)?

Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support? Is there an appropriate degree of commitment and cooperation of institutions involved in program delivery as evidenced by letters detailing the nature and extent of the involvement?

The primary review will be a peer review conducted by HHS/CDC/NCIPC Initial Review Group (IRG). Applications may be subjected to a preliminary evaluation (streamline review) by the IRG to determine if the application is of sufficient technical and scientific merit to warrant further review. HHS/CDC/NCIPC will withdraw from further consideration applications judged to be noncompetitive and promptly notify the principal investigator/program director and the official signing for the applicant organization. Those applications judged to be competitive will be further evaluated by the IRG. These applications will be reviewed for scientific merit using current NIH criteria (a scoring system of 100 - 500 points) to evaluate the methods and scientific quality of the application.

The secondary review will be conducted by the Science and Program Review Subcommittee (SPRS) of the Advisory Committee for Injury Prevention and Control (ACIPC). The ACIPC Federal agency experts will be invited to attend the secondary review and will receive modified briefing books (i.e., abstracts, strengths and weaknesses from summary statements, and project officer’s briefing materials). ACIPC Federal agency experts will be encouraged to participate in deliberations when applications address overlapping areas of research interest, so that unwarranted duplication in federally-funded research can be avoided and special subject area expertise can be shared. The HHS/CDC/NCIPC Division Associate Directors for Science (ADS) or their designees will attend the secondary review in a similar capacity as the ACIPC Federal agency experts to assure that research priorities of the announcement are understood and to provide background regarding current research activities. Only SPRS members will vote on funding recommendations, and their recommendations will be carried to the entire ACIPC for voting by the ACIPC members in closed session. If any further review is needed by the ACIPC, regarding the recommendations of the SPRS, the factors considered will be the same as those considered by the SPRS.

The ACIPC committee’s responsibility is to develop funding recommendations for the HHS/CDC/NCIPC Director based on the results of the primary review, the relevance and balance of proposed research relative to the HHS/CDC/NCIPC programs and priorities, and to assure that unwarranted duplication of federally-funded research does not occur. The secondary review committee has the latitude to recommend to the HHS/CDC/NCIPC Director, to reach over better ranked proposals in order to assure maximal impact and balance of proposed research. The factors to be considered will include:

All awards will be determined by the Director of the HHS/CDC/NCIPC based on priority scores assigned to applications by the primary review committee IRG, recommendations by the secondary review committee of the Science and Program Review Subcommittee of the ACIPC, consultation with HHS/CDC/NCIPC senior staff, and the availability of funds.

Continuation awards made after FY 2007, but within the project period, will be made on the basis of the availability of funds and the following criteria:

Grantees will be notified in August or early September of 2007 by HHS/CDC’s Procurement and Grants Office (PGO) if their applications were selected for funding. It is anticipated that awards will be made in September 2007.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the Grants Management Officer (GMO) is the authorizing document. This document will be mailed and/or emailed to the recipient fiscal officer and PD/PI identified in the application.

Selection of the application for award is not an authorization to begin performance. Any cost incurred before receipt of the NoA is at the recipient’s risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.

The Code of Federal Regulations 45 CFR Part 74 and Part 92 have details about policy requirements. For more information on the Code of Federal Regulations, see the National Archives and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html  Additional requirements are available in Section VIII. Other Information on this document or on the CDC website at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm  These will be incorporated into the NoA by reference.

The Recipient will have the primary responsibility for the following:

Additionally, an HHS/CDC agency program official or CIO program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the NoA.

Recipient Organization must provide HHS/CDC with an original, plus two hard copies of the following reports:

Recipient Organization must forward these reports by the U.S. Postal Service or express delivery to the Grants Management Specialist listed in the "Agency Contacts" section of this NoA.

Although the financial plans of the HHS/CDC CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.

Tamara Haegerich, Ph.D.

Scientific Program Administrator

National Center for Injury Prevention and Control

Centers for Disease Control and Prevention (CDC)

U.S. Department of Health and Human Services

4770 Buford Hwy, NE, Mailstop K-60

Atlanta, GA 30341

Telephone: (770) 488-4284

FAX: (770) 488-1011

Email: thaegerich@cdc.gov

Gwendolyn Cattledge, Ph.D.

Scientific Review Administrator

National Center for Injury Prevention and Control

Centers for Disease Control and Prevention (CDC)

U.S. Department of Health and Human Services

4770 Buford Hwy, NE, Mailstop K-02

Atlanta, GA 30341

Telephone: (770) 488-1430

FAX: (770) 488-4422

Brenda Hayes, Grants Management Specialist

Procurement and Grants Office

Center for Disease Control and Prevention

U.S. Department of Health and Human Services

Colgate Building, Room 3217

2920 Brandywine Rd.

Atlanta, GA 30341

Telephone: (770) 488-2741

FAX: (770) 488-2670

Email: BHayes@cdc.gov

CDC Procurement and Grants Office

U.S. Department of Health and Human Services

2920 Brandywine Road

Atlanta, GA 30341

Telephone: 770-488-2700

Email: PGOTIM@cdc.gov

NCIPC Website: For additional help in preparing your grant application please see the "frequently asked questions" section on the NCIPC webpage at: http://www.cdc.gov/ncipc/res-opps/2004pas.htm

Conference Call

Technical assistance will be available for potential applicants on one conference call. The call for eligible applicants will be held on November 1, 2006, at 1:00 p.m. (Eastern Time). The conference call can be accessed by calling 1-800-369-1121 and using access code LPATTERSON. The purpose of the conference call is to help potential applicants:

(1.) understand the request for application process for CDC-FOA-CE07-002 entitled Family and Dyadic Focused Interventions to Prevent Intimate Partner Violence (U49); (2) understand the scope and intent of CDC-FOA-CE07-002, and (3) become familiar with the Public Health Services funding policies and application and review procedures. Participation in this conference call is not mandatory. At the time of the call, if you have problems accessing the conference call, please call 1-800-857-8777 for assistance.

Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm  Additional HHS/CDC Requirements under AR-1 Human Subjects Requirements can be found on http://www.cdc.gov/od/pgo/funding/ARs.htm

Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research

It is the policy of the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) to ensure that individuals of both sexes and the various racial and ethnic groups will be included in CDC/ATSDR-supported research projects involving human subjects, whenever feasible and appropriate. Racial and ethnic groups are those defined in OMB Directive No. 15 and include American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific Islander. Applicants shall ensure that women, racial and ethnic minority populations are appropriately represented in applications for research involving human subjects. Where clear and compelling rationale exist that inclusion is inappropriate or not feasible, this situation must be explained as part of the application. This policy does not apply to research studies when the investigator cannot control the race, ethnicity, and/or sex of subjects. Further guidance to this policy is contained in the Federal Register, Vol. 60, No. 179, pages 47947-47951, and dated Friday, September 15, 1995.

The policy of CDC is that persons under the age of 21 must be included in all human subjects research that is conducted or supported by CDC, unless there are scientific and ethical reasons not to include them. This policy applies to all CDC-conducted or CDC-supported research involving human subjects, including research that is otherwise exempt in accordance with Sections 101(b) and 401(b) of 45 C.F.R. Part 46, HHS Policy for the Protection of Human Subjects. Therefore, proposals for research involving human subjects must include a description of plans for including persons under the age of 21. If persons under the age of 21 will be excluded from the research, the application or proposal must present an acceptable justification for the exclusion.

In an extramural research plan, the investigator should create a section titled "Participation of persons under the age of 21." This section should provide either a description of the plans to include persons under the age of 21 and a rationale for selecting or excluding a specific age range, or an explanation of the reason(s) for excluding persons under the age of 21 as participants in the research. When persons under the age of 21 are included, the plan must also include a description of the expertise of the investigative team for dealing with individuals at the ages included, the appropriateness of the available facilities to accommodate the included age groups, and the inclusion of a sufficient number of persons under the age of 21 to contribute to a meaningful analysis relative to the purpose of the study. Scientific review groups at CDC will assess each application as being acceptable or unacceptable in regard to the age-appropriate inclusion or exclusion of persons under the age of 21 in the research project, in addition to evaluating the plans for conducting the research in accordance with these provisions.

The inclusion of children (as defined by the applicable law of the jurisdiction in which the research will be conducted) as subjects in research must be in compliance with all applicable subparts of 45 C.F.R. Part 46, as well as with other pertinent federal laws and regulations.

The policy of inclusion of persons under the age of 21 in CDC-conducted or CDC-supported research activities in foreign countries (including collaborative activities) is the same as that for research conducted in the United States.

Under the Paperwork Reduction Act, projects that involve the collection of information from 10 or more individuals and funded by a grant or a cooperative agreement will be subject to review and approval by the Office of Management and Budget (OMB).

CDC strongly encourages all recipients to provide a smoke-free workplace and to promote abstinence from all tobacco products. Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, or early childhood development services are provided to children.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.healthypeople.gov 

Applicants should be aware of restrictions on the use of HHS funds for lobbying of Federal or State legislative bodies. Under the provisions of 31 U.S.C. Section 1352, recipients (and their sub-tier contractors) are prohibited from using appropriated Federal funds (other than profits from a Federal contract) for lobbying congress or any Federal agency in connection with the award of a particular contract, grant, cooperative agreement, or loan. This includes grants/cooperative agreements that, in whole or in part, involve conferences for which Federal funds cannot be used directly or indirectly to encourage participants to lobby or to instruct participants on how to lobby.

In addition no part of CDC appropriated funds, shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before the Congress or any State or local legislature, except in presentation to the Congress or any State or local legislature itself. No part of the appropriated funds shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress or any State or local legislature.

Any activity designed to influence action in regard to a particular piece of pending legislation would be considered "lobbying." That is lobbying for or against pending legislation, as well as indirect or "grass roots" lobbying efforts by award recipients that are directed at inducing members of the public to contact their elected representatives at the Federal or State levels to urge support of, or opposition to, pending legislative proposals is prohibited. As a matter of policy, HHS/CDC extends the prohibitions to lobbying with respect to local legislation and local legislative bodies.

The provisions are not intended to prohibit all interaction with the legislative branch, or to prohibit educational efforts pertaining to public health. Clearly there are circumstances when it is advisable and permissible to provide information to the legislative branch in order to foster implementation of prevention strategies to promote public health. However, it would not be permissible to influence, directly or indirectly, a specific piece of pending legislation

It remains permissible to use HHS/CDC funds to engage in activity to enhance prevention; collect and analyze data; publish and disseminate results of research and surveillance data; implement prevention strategies; conduct community outreach services; provide leadership and training, and foster safe and healthful environments.

Recipients of HHS/CDC grants and cooperative agreements need to be careful to prevent CDC funds from being used to influence or promote pending legislation. With respect to conferences, public events, publications, and "grassroots" activities that relate to specific legislation, recipients of HHS/CDC funds should give close attention to isolating and separating the appropriate use of HHS/CDC funds from non-CDC funds. HHS/CDC also cautions recipients of HHS/CDC funds to be careful not to give the appearance that HHS/CDC funds are being used to carry out activities in a manner that is prohibited under Federal law.

The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act specifies that: "None of the funds made available for injury prevention and control at the Centers for Disease Control and Prevention may be used to advocate or promote gun control."

Anti-Lobbying Act requirements prohibit lobbying Congress with appropriated Federal monies. Specifically, this Act prohibits the use of Federal funds for direct or indirect communications intended or designed to influence a member of Congress with regard to specific Federal legislation. This prohibition includes the funding and assistance of public grassroots campaigns intended or designed to influence members of Congress with regard to specific legislation or appropriation by Congress.

In addition to the restrictions in the Anti-Lobbying Act, HHS/CDC interprets the language in the HHS/CDC's Appropriations Act to mean that HHS/CDC's funds may not be spent on political action or other activities designed to affect the passage of specific Federal, State, or local legislation intended to restrict or control the purchase or use of firearms.

Proof of nonprofit status must be submitted by private nonprofit organizations with the application. Any of the following is acceptable evidence of nonprofit status: (a) a reference to the applicant organization's listing in the Internal Revenue Service's (IRS) most recent list of tax-exempt organizations described in section 501(c)(3) of the IRS Code; (b) a copy of a currently valid IRS tax exemption certificate; (c) a statement from a State taxing body, State Attorney General, or other appropriate State Official certifying that the applicant organization has a nonprofit status and that none of the net earnings accrue to any private shareholders or individuals; (d) a certified copy of the organization's certificate of incorporation or similar document that clearly establishes nonprofit status; (e) any of the above proof for a State or national parent organization and a statement signed by the parent organization that the applicant organization is a local nonprofit affiliate.

Small, Minority, And Women-owned Business

It is a national policy to place a fair share of purchases with small, minority and women-owned business firms. The Department of Health and Human Services is strongly committed to the objective of this policy and encourages all recipients of its grants and cooperative agreements to take affirmative steps to ensure such fairness. In particular, recipients should:

The signature of the institution official on the face page of the application submitted under this Funding Opportunity Announcement is certifying compliance with the Department of Health and Human Services (DHHS) regulations in Title 42 Part 50, Subparts A-E, entitled PUBLIC HEALTH SERVICE POLICIES ON RESEARCH MISCONDUCT.

The regulation places requirements on institutions receiving or applying for funds under the PHS Act that are monitored by the DHHS Office of Research Integrity's (ORI)  http://ori.hhs.gov./policies/statutes.shtml  

For example:

Section 93.301 Institutional assurances.(a) General policy. An institution with PHS supported biomedical or behavioral research, research training or activities related to that research or research training must provide PHS with an assurance of compliance with this part, satisfactory to the Secretary. PHS funding components may authorize [[Page 28389]] funds for biomedical and behavioral research, research training, or activities related to that research or research training only to institutions that have approved assurances and required renewals on file with ORI. (b) Institutional Assurance. The responsible institutional official must assure on behalf of the institution that the institution-- (1) Has written policies and procedures in compliance with this part for inquiring into and investigating allegations of research misconduct; and (2) Complies with its own policies and procedures and the requirements of this part.

Faith-based organization are eligible to receive federal financial assistance, and their applications are evaluated in the same manner and using the same criteria as those for non-faith-based organizations in accordance with Executive Order 13279, Equal Protection of the Laws for Faith-Based and Community Organizations. All applicants should, however, be aware of restrictions on the use of direct financial assistance from the Department of Health and Human Services (DHHS) for inherently religious activities. Under the provisions of Title 45, Parts 74, 87, 92 and 96, organizations that receive direct financial assistance from DHHS under any DHHS program may not engage in inherently religious activities, such as worship, religious instruction, or proselytization as a part of the programs or services funded with direct financial assistance from DHHS. If an organization engages in such activities, it must offer them separately, in time or location, from the programs or services funded with direct DHHS assistance, and participation must be voluntary for the beneficiaries of the programs or services funded with such assistance. A religious organization that participates in the DHHS funded programs or services will retain its independence from Federal, State, and local governments, and may continue to carry out its mission, including the definition, practice, and expression of its religious beliefs, provided that it does not use direct financial assistance from DHHS to support inherently religious activities such as those activities described above. A faith-based organization may, however, use space in its facilities to provide programs or services funded with financial assistance from DHHS without removing religious art, icons, scriptures, or other religious symbols. In addition, a religious organization that receives financial assistance from DHHS retains its authority over its internal governance, and it may retain religious terms in its organization= s name, select its board members on a religious basis, and include religious references in its organization= s mission statements and other governing documents in accordance with all program requirements, statutes, and other applicable requirements governing the conduct of DHHS funded activities. For further guidance on the use of DHHS direct financial assistance see Title 45, Code of Federal Regulations, Part 87, Equal Treatment for Faith-Based Organizations, and visit the internet site:

http://www.whitehouse.gov/government/fbci/

Recipients of this grant award should note that pursuant to the Standards for Privacy of Individually Identifiable Health Information promulgated under the Health Insurance Portability and Accountability Act (HIPAA) (45 CFR Parts 160 and 164) covered entities may disclose protected health information to public health authorities authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions. The definition of a public health authority includes a person or entity acting under a grant of authority from or contract with such public agency. HHS/CDC considers this project a public health activity consistent with the Standards for Privacy of Individually Identifiable Health Information and CDC will provide successful recipients a specific grant of public health authority for the purposes of this project.

The Data Release Plan is the Grantee's assurance that the dissemination of any and all data collected under the CDC data sharing agreement will be released as follows:

April 16, 2003, http://www.cdc.gov/od/foia/policies/sharing.htm  and in full compliance with the 1996 Health Insurance Portability and Accountability Act (HIPPA), (where applicable), The Office of Management and Budget Circular A110, (2000) revised 2003, www.whitehouse.gov/omb/query.html?col=omb&qt=Releasing+and+Sharing+of+Data  and Freedom of Information Act (FOIA) www.4.law.cornell.edu/uscode/5/5/552/html

Applications must include a copy of the applicant's Data Release Plan.  Applicants should provide CDC with appropriate documentation on the reliability of the data.  Applications submitted without the required Plan may be ineligible for award.  Award will be made when reviewing officials have approved an acceptable Plan.  The successful applicant and the Program Manager will determine the documentation format.  HHS/CDC recommends data is released in the form closest to micro data and one that will preserve confidentiality. 

Conference Disclaimer and Use of Logos

Disclaimer: Where a conference is funded by a grant or cooperative agreement, a subgrant or a contract the recipient must include the following statement on conference materials, including promotional materials, agenda, and internet sites:

Logos: Neither the HHS nor the CDC ("CDC" includes ATSDR) logo may be displayed if such display would cause confusion as to the source of the conference or give the false appearance of Government endorsement. A non-federal entity’s unauthorized use of the HHS name or logo is governed by U.S.C. § 1320b-10, which prohibits the misuse of the HHS name and emblem in written communication. The appropriate use of the HHS logo is subject to the review and approval of the Office of the Assistant Secretary for Public Affairs (OASPA). Moreover, the Office of the Inspector General has authority to impose civil monetary penalties for violations (42 C.F.R. Part 1003). Neither the HHS nor the CDC logo can be used on conference materials under a grant, cooperative agreement, contract or co-sponsorship agreement without the expressed, written consent of either the Project Officer or the Grants Management Officer. It is the responsibility of the grantee (or recipient of funds under a cooperative agreement) to request consent for the use of the logo in sufficient detail to assure a complete depiction and disclosure of all uses of the Government logos, and to assure that in all cases of the use of Government logos, the written consent of either the Project Officer or the Grants Management Officer has been received.